Oncology & Cancer

Studies of personalized cell therapies define optimal doses

More precise dosing methods and cellular engineering techniques show promise in the effort to improve treatment of aggressive cancers with personalized cellular therapies, according to new studies from researchers in the ...

Oncology & Cancer

Venclexta approved for specific genetic blood cancer

(HealthDay)—Venclexta (venetoclax) has been approved by the U.S. Food and Drug Administration to treat chronic lymphocytic leukemia (CLL) characterized by a specific chromosomal abnormality called the 17p deletion.

Oncology & Cancer

CYP3A7*1C allele linked to cancer mortality, progression

(HealthDay)—The CYP3A7*1C allele appears to be associated with mortality and disease progression in specific cancers, according to a study published online March 10 in Cancer Research.

Oncology & Cancer

New immune Tx achieves remission in B-cell malignancies

(HealthDay)—A new T-cell immunotherapy has led to sustained regression in many previously relapsing and treatment-resistant cases of acute lymphoblastic leukemia, non-Hodgkin's lymphoma, and chronic lymphocytic leukemia, ...

page 8 from 15